Search
Incyte Corp
INCYAdd to Watchlist
125.010USD
+1.790+1.45%
Close 08-31 16:00（ET）
25.10BMarket Cap
17.12P/E TTM
Forecast
Currency: USD Updated: 2026-08-31The current earnings forecast score of Incyte Corp is 7.33, ranking 103 out of 158 in the Pharmaceuticals industry. The average price target is 101.00, with a high of 129.00 and a low of 70.00.
Analyst Rating
Based on
29
analysts
Buy
Current Rating
127.510
Target Price
+2.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Incyte Corp
INCY
29
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Regeneron Pharmaceuticals Inc
REGN
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Incyte Corp's expected revenue for the next quarter?
Incyte Corp's expected revenue is 1.48B.
What is Incyte Corp's price target?
Analysts forecast that Incyte Corp's price target is USD 101.00, with the highest forecast at USD 129.00 and the lowest forecast at USD 70.00.
How have Incyte CorpINCY's recent earnings per share performed?
The market expectation was USD 2.92, while Incyte CorpINCY's earnings per share (EPS) for the previous quarter was USD 1.52. EPS for the next quarter is expected at USD -3.39.
What is the analyst rating for Incyte Corp?
Based on the ratings of Incyte Corp's stock from 29 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.